Salte directo a la búsqueda Salte directo al listado de A-Z Salte directo a la navegación Salte directo al contenido Salte directo a las opciones de la página
CDC Home
Share
Compartir

Appendices 

Appendix C: Travel Vaccine Summary Table

David R. Shlim

Table C-01 is a quick reference for administering or prescribing travel-related vaccines. Before administering any vaccine, please pay particular attention to the dose and whether it is to be administered intramuscularly or subcutaneously. Also review detailed instructions, contraindications, precautions, and side effects under the specific vaccines discussed in this book or in the manufacturer’s package insert. For other immunizations, refer to the corresponding disease section in Chapter 3.

Table C-01. Travel vaccine summary

VACCINE BRAND NAME DOSE ROUTE SCHED-
ULE
BOOSTER AGE
Hepatitis A (adult) Havrix 1.0 mL (1,440 ELISA units) IM 0 and 6–12 months None ≥19 years
Vaqta 1.0 mL (50 units) IM 0 and 6–18 months None ≥19 years
Hepatitis A (pediatric) Havrix 0.5 mL (720 ELISA units) IM 0 and 6–12 months None 1–18 years
Vaqta 0.5 mL (25 units) IM 0 and 6–18 months None 1–18 years
Combined hepatitis A and hepatitis B Twinrix 1.0 mL (20μg of hepatitis B antigen and 720 ELISA units of hepatitis A antigen) IM 0, 1 month, and 6 months; acceler-
ated schedule: days 0, 7, and 21–30, with a fourth dose at 12 months
None ≥18 years
Hepatitis B (adult) Engerix-B 1.0 mL (20μg) IM 0, 1 month, and 6 months; can be given on an accelerated schedule of 0, 1 month, 2 months, and 12 months None ≥20 years
Recombivax HB 1.0 mL (20μg) IM >0, 1 month, and 6 months None ≥20 years
Hepatitis B (pediatric) Engerix-B 0.5 mL (10μg) IM 0, 1 month, and 6 months; can be given on an accelerated schedule of 0, 1 month, 2 months, and 12 months. If using an accelerated schedule, give 0.5 mL (10 μg) for ages birth through 10 years and 1.0 mL (20 μg) for ages 11–19 years None ≤19 years
Recombivax HB (primary) 0.5 mL (5μg) IM 0, 1 month, and 6 months None ≤19 years
Recombivax HB (adolescent accelerated) 1.0 mL (10μg) IM 0, 4–6 months None For ages 11–15 years
Japanese encepha-
litis
Ixiaro 0.5 mL IM 0 and 28 days ≥1 year after primary series1 ≥17 years1
Meningo-
coccal conjugate (MenACWY)
Menactra
(MenACWYD)
0.5 mL IM 2-dose primary series separated by 3 months See Chapter 3, Meningo-
coccal Disease
9-23 months
   0.5 mL IM 1 dose See Chapter 3, Meningo-
coccal Disease
 2–55 years
Menveo
(MenACWYCRM)
0.5 mL IM 1 dose See Chapter 3, Meningo-
coccal Disease
2–55 years
Meningo-
coccal polysac-
charide (MPSV4)
Meno-
mune
0.5 mL SC 1 dose See Chapter 3, Meningo-
coccal Disease
≥2 years
Inacti-
vated polio (adult)
Ipol 0.5 mL SC or IM 1 dose at ≥18 years, if patient has already had an accept-
able polio vaccine series
None ≥18 years2
Rabies Imovax 1.0 mL IM Preexposure series: days 0, 7, and 21 or 28 See Chapter 3, Rabies No age restric-
tions
RabAvert 1.0 mL IM Preexposure series: days 0, 7, and 21 or 28 See Chapter 3, Rabies No age restric-
tions
Typhoid capsular polysac-
charide
Typhim Vi 0.5 mL IM 1 dose Every 2 years ≥2 years
Typhoid oral, live, attenu-
ated
Vivotif 1 pill Oral 1 pill every other day for 4 doses Every 5 years ≥6 years
Yellow fever YF-Vax 0.5 mL SC 1 dose Every 10 years ≥9 months, same dose for children and adults3

Abbreviations: ELISA, enzyme-linked immunosorbent assay; IM, intramuscular; SC, subcutaneous.

1See Chapter 3, Japanese Encephalitis. Data on the response to a booster dose administered ≥2 years after the primary series are not available. Data on the need for and timing of additional booster doses are also not available. Ixiaro may be approved for use in children when studies are completed.
2For catch-up immunization in pediatric population, see Table 7-02.
3Special considerations apply in deciding whether to administer yellow fever vaccine. Please review Chapter 3, Yellow Fever before administration. Yellow fever vaccine is never given to infants <6 months and is given with precaution and only under special circumstances for ages 6–8 months. There is also a precaution for its use in patients aged ≥60 years.

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC-INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #